1H,3H,4H,6H,7H-furo[3,4-c]pyran-1,3-dione | 2171110-69-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异苯并呋喃
• 英文名称: 1H,3H,4H,6H,7H-furo[3,4-c]pyran-1,3-dione
• 英文别名: 6,7-dihydro-4H-furo[3,4-c]pyran-1,3-dione
• CAS: 2171110-69-1
• 化学式: C₇H₆O₄
• 分子量: 154.12
• InChiKey: JCBMWZOVLSJQLX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] (--)- HUPERZINE A PROCESSES AND RELATED COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] PROCÉDÉS DE FABRICATION DE (-) HUPERZINE A, COMPOSITIONS ASSOCIÉES, ET MÉTHODES DE TRAITEMENT
  申请人：UNIV YALE

  公开号：WO2012121863A1

  公开（公告）日：2012-09-13

  The invention provides (1) processes for making substantially-pure (-) huperzine A and substantially-pure (-) huperzine A derivatives; (2) compositions useful in making substantially-pure (-) huperzine A and substantially-pure (-) huperzine A derivatives; and (3) methods of treating or preventing neurological disorders using substantially-pure (-) huperzine A and substantially-pure (-) huperzine A derivatives.

  该发明提供了三个方面：(1) 制备几乎纯的(-)华佩嗪A和几乎纯的(-)华佩嗪A衍生物的过程；(2) 用于制备几乎纯的(-)华佩嗪A和几乎纯的(-)华佩嗪A衍生物的组合物；以及(3) 使用几乎纯的(-)华佩嗪A和几乎纯的(-)华佩嗪A衍生物治疗或预防神经系统疾病的方法。
• INTERMEDIATE COMPOUNDS UTILIZABLE IN SYNTHESIS OF (-) HUPERZINE AND PROCESS FOR OBTAIN ONE OF THESE INTERMEDIATE COMPOUNDS
  申请人：Yale University

  公开号：EP3434669A1

  公开（公告）日：2019-01-30

  The invention provides Intermediate compounds utilizable in synthesis of (-)-Huperzine and process for obtain one of these intermediate compounds.

  本发明提供了可用于合成 (-)-Huperzine 的中间体化合物以及获得这些中间体化合物之一的工艺。
• (−)-Huperzine A processes and related compositions and methods of treatment
  申请人：Herzon Seth

  公开号：US10059672B2

  公开（公告）日：2018-08-28

  The invention provides (1) processes for making substantially-pure (−) huperzine A and substantially-pure (−) huperzine A derivatives; (2) compositions useful in making substantially-pure (−) huperzine A and substantially-pure (−) huperzine A derivatives; and (3) methods of treating or preventing neurological disorders using substantially-pure (−) huperzine A and substantially-pure (−) huperzine A derivatives.

  本发明提供了（1）制造实质上纯净的（-）虎佩嗪 A 和实质上纯净的（-）虎佩嗪 A 衍生物的工艺；（2）用于制造实质上纯净的（-）虎佩嗪 A 和实质上纯净的（-）虎佩嗪 A 衍生物的组合物；以及（3）使用实质上纯净的（-）虎佩嗪 A 和实质上纯净的（-）虎佩嗪 A 衍生物治疗或预防神经系统疾病的方法。
• (−)-huperzine A processes and related compositions and methods of treatment
  申请人：Yale University

  公开号：US10457643B2

  公开（公告）日：2019-10-29

  The invention provides (1) processes for making substantially-pure (−) huperzine A and substantially-pure (−) huperzine A derivatives; (2) compositions useful in making substantially-pure (−) huperzine A and substantially-pure (−) huperzine A derivatives; and (3) methods of treating or preventing neurological disorders using substantially-pure (−) huperzine A and substantially-pure (−) huperzine A derivatives.

  本发明提供了（1）制造实质上纯净的（-）虎佩嗪 A 和实质上纯净的（-）虎佩嗪 A 衍生物的工艺；（2）用于制造实质上纯净的（-）虎佩嗪 A 和实质上纯净的（-）虎佩嗪 A 衍生物的组合物；以及（3）使用实质上纯净的（-）虎佩嗪 A 和实质上纯净的（-）虎佩嗪 A 衍生物治疗或预防神经系统疾病的方法。
• Pyridazinone-based broad spectrum anti-influenza inhibitors
  申请人：Hoffmann-La Roche Inc.

  公开号：US10597380B2

  公开（公告）日：2020-03-24

  The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.

  本发明涉及式（I）化合物： 或其药学上可接受的盐类，以及它们的制造工艺、包含它们的药物组合物和它们作为药物的用途。